Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
ANIK
#2994
Anika Therapeutics Inc
14.360
0
+14.42%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
+14.42%
Monatliche Änderung
+55.50%
6 month change
+41.62%
Jahresänderung
+41.62%
Vorheriger Schlusskurs
12.550
0
Open
14.360
0
Bid
Ask
Low
14.360
0
High
14.360
0
Volumen
44
Märkte
Aktien
Gesundheitswesen
ANIK
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
14.65 M
14.18 M
14.34 M
14.42 M
14.42 M
—
Valuation ratios
Enterprise value
299.38 M
177.71 M
162.18 M
99.38 M
77.57 M
516.83 M
Price to earnings ratio
-3.72
-4.3
-3.88
-2.56
-4.14
-14.88
Price to sales ratio
2.22
2.02
1.61
1.25
1.21
6.08
Price to cash flow ratio
2 420.76
44.85
41.02
34.42
16.73
137.02
Price to book ratio
0.45
1.57
0.32
0.24
0.23
2.37
Enterprise value to EBITDA ratio
-3.06
-29.24
-4.03
-2.31
-5.42
-41.01
Profitability ratios
Return on assets %
0.13
0.11
0.03
0.02
0.01
0.17
Return on equity %
0.17
0.14
0.03
0.03
0.02
0.22
Return on invested capital %
78.13
11.56
16.09
13.94
8.06
49.65
Gross margin %
3.72
55.96
56.1
50.9
56.02
218.99
Operating margin %
72.3
2.3
16.37
14.81
11.62
45.11
EBITDA margin %
-82.43
-9.2
-15.34
-14.78
-11.9
-51.21
Net margin %
77.2
71.45
18.62
14.07
8.37
112.51
Liquidity ratios
Quick ratio
3.78
3.85
4.53
5.12
4.47
17.98
Current ratio
5.34
4.88
5.73
6.18
5.32
22.1
Inventory turnover
1.04
0.42
0.51
0.72
0.74
2.39
Asset turnover
0.16
0.14
0.13
0.15
0.15
0.57
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.18
0.11
0.01
0.01
0.43
0.56
EBIT per share
-2.18
-0.33
-0.38
-0.39
-0.33
-1.42
EBITDA per share
-2.16
-0.19
-0.28
-0.29
-0.23
-0.99
Total debt per share
—
—
—
—
—
—
Cash per share
6.14
5.38
5.27
5.31
5.56
21.53
Net current asset value per share
9.22
7.72
7.17
6.84
7.05
28.78
Tangible book value per share
11.45
9.81
9.7
9.5
9.51
38.52
Working capital per share
7.49
6.14
5.92
5.73
5.72
23.51
Book value per share
12.18
10.46
10.38
10.17
10.18
41.19
Nachrichten
Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates
Anika Q4 2025: Starkes kommerzielles Wachstum kompensiert Rückgang im OEM-Geschäft/n
Anika Q4 2025 slides: commercial surge offsets OEM decline
Anika: EPS übertrifft Schätzungen um 0,45 $ - Umsatz besser als erwartet
Anika earnings beat by $0.45, revenue topped estimates
Lumicell appoints Cheryl Blanchard to board of directors
Führungswechsel bei Anika Therapeutics: Stephen Griffin wird neuer CEO
Anika Therapeutics names Stephen Griffin as new CEO
Anika Q3 2025: Kommerzielles Wachstum gleicht OEM-Rückgang aus
Anika Q3 2025 slides: Commercial growth offsets OEM decline
Anika Therapeutics (ANIK) Q3 Earnings and Revenues Top Estimates
Anika earnings beat by $0.22, revenue was in line with estimates